Early PSA response correlates with better outcomes in mHSPC patients receiving ADT and ARPIs.

Zelenirstat, an effective oral NMT inhibitor, showed promising results in treating advanced relapsed/refractory cancer at 2024's ASCO_GI.

Tinengotinib, a selective multi-kinase inhibitor, effectively targets FGFR2 fusion/rearrangement and resistance mutations in early trials involving cholangiocarcinoma patients.

Tasurgratinib (E7090) is an orally available selective inhibitor of FGFR 1–3, the recommended dose is 140 mg per day per the dose-escalation part of a first-in-human phase 1 study.

Colorectal cancer (CRC) ranks second in US cancer deaths. 5-fluorouracil (5-FU) therapies with targeted drugs are the go-to for advanced cases.

The initial FOLFIRINOX protocol for PDAC carries a high FN risk; pegfilgrastim mitigates this, but optimal duration is uncertain.

LY3537982: A Potent Oral Inhibitor for KRAS G12C Mutation in GI Tumors - Results from 2024 ASCO-GI LOXO-RAS-20001 Phase 1 Study.

The phase II trial of mFOLFIRINOX, followed by hepatic infusion of floxuridine & dexamethasone with mFOLFIRI as first-line treatment in intrahepatic cholangiocarcinoma patients (HELIX-1), was presented at 2024 ASCO_GI on Jan 18.

CRC, marked by Wnt pathway hyperactivation and DKK1 regulation, is effectively countered by DKN-01, an IgG4 antibody that neutralizes DKK1.

Phase 2 results of IL-27, PD-(L)1, VEGF blockade using casdozokitug, atezo, and bev in uHCC patients were presented at 2024 ASCO_GI on Jan 18th.

The latest clinical results of ADG-126 for metastatic MSS CRC treatment were shared at the 2024 ASCO_GI on Jan 20, 2024.

Based on previous studies, biomarker analysis from Phase 1/2 study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC) was reported at the AACR Congress.